Against the background of my first post on this thread and the...

Against the background of my first post on this thread and the previous question by@Amit9997 I am happy to outline the "things in the pipeline" for the next 3-6 months and what to expect beyond that. Note that these statements are consistent with recent and past announcements, and statements made by me in recent interviews and webinars. Here we go:

1. Sales in current markets: Over the last year - the first full year of Nasodine sales - we have seen strong quarterly growth in sales (see our December 2024 half-year report, March 2025 quarterly activity report and our Investor Update released last week). You would expect good sales growth in the first year of a successful new product. Bear in mind that we couldn't have reported this if Nasodine had been a dud in the market and most new products do fail in their first year. Not so with Nasodine, where we have seen strong adoption, 100% positive product reviews and high sales growth. That's an important 'commercial risk' factor that is largely extinguished.
In the annual report (due in August) I expect we will report in more detail on the sales performance by market and that should provide a clear trajectory for future sales projections. Bear in mind, we are in only three markets so far: US, Singapore and Fiji.

1(a) Quick note on US market: We had hoped to ramp up our marketing investment in the US to accelerate sales and gain pharmacy distribution in the US, but after our recent abortive fundraising attempt, we won't have the extra funds to support that, so we will keep the US business focused on online sales, which are profitable, cost little to run and are growing nicely.

2. New markets: You can expect us to announce important milestones in the pathway towards approval in the Philippines, including (as telegraphed in the March 2025 quarterly) the filing by our partner, SV More Pharma, of the registration dossier for Nasodine Nasal Spray in the Philippines. After that, the next major milestone will be approval by the Philippines FDA and product launch, which is expected around mid-year in calendar 2026.

As previously reported, we do not expect any problems with approval in the Philippines, but it will be an important milestone because it will represent our first genuine regulatory approval in any market. Remember, as part of our fast-to-market strategy for Nasodine, we are currently marketing the product in countries that do not require formal regulatory approval. The Philippines approval not only gives us a real regulatory approval but it provides us with a COPP (Certificate Of Pharmaceutical Product) which is granted by the national health authority and certifies local approval, and a FSC (Free Sale Certificate), that confirms that the pharmaceutical product is legally permitted for sale in its country and meets the necessary standards for export. The FSC and COPP are prerequisites (and provide a shortcut) to registration of an OTC product in many countries, including most countries in Asia, Latin America and Middle East. Basically, the FSC/COPP is a massive door-opener to global markets, and the Philippines approval delivers that for us.
Apart from the Philippines, which has 20 times the population of Singapore, there are other large and small markets in SE Asia that we can enter with expedited registration processes. In the next few months, expect an announcement about registration activity in multiple markets and the approval and launch of Nasodine Nasal Spray in at least one new market.

3. New Products: We have several new products beyond Nasodine Nasal Spray and each of these gives us a new stream of value creation and enhances the value of the Nasodine portfolio. Expect an announcement about the launchof at least one new Nasodine-brand product into all existing markets.

Not much more I can tell you for now, expect that everything is heading in the right direction from our perspective.

Regards to all supporters,
Peter Molloy